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Definitions, abbreviations and
acronyms
Definitions
Atrial high rate event (AHRE): atrial high-rate episodes are defined as
atrial tachyarrhythmia episodes with rate >190 beats/min detected
by cardiac implantable electronic devices.
Subclinical atrial fibrillaton (AF): atrial high-rate episodes (>6
minutes and <24-hours) with lack of correlated symptoms in patients
with cardiac implantable electronic devices, detected with continu-
ous ECG monitoring (intracardiac) and without prior diagnosis (ECG
or Holter monitoring) of AF.
Silent (asymptomatic) AF: documented AF in the absence of any
symptoms or prior diagnosis often presenting with a complication
related to AF e.g. stroke, heart failure, etc.
Excessive supraventricular ectopic activity (ESVEA): 30 premature
supraventricular contractions (PSC) /hour (>_729 PCS /24 hours) or
episode of PSC runs >_20 beats.
Abbreviations and acronyms
AF - atrial fibrillation
AHRE – atrial high rate episode
ASSERT – ASymptomatic atrial fibrillation and Stroke Evaluation in
pacemaker patients and atrial fibrillation Reduction atrial pacing Trial
AT – atrial tachyarrhythmia
AVB – atrioventricular block
BEATS – Balanced Evaluation of Atrial Tachyarrhythmias in
Stimulated patients
CHADS2 – Cardiac failure, Hypertension, Age, Diabetes, Stroke
(doubled)
CHA2DS2-VASc – Congestive heart failure or left ventricular dys-
function, Hypertension, Age >_75 (doubled), Diabetes, Stroke/
Transient Ischaemic Attack (doubled)-Vascular Disease, Age 65-74,
Sex category (female)
CI – confidence interval
CIED – cardiac implantable electronic device
CRT – cardiac resynchronization therapy device
CRYSTAL – CRYptogenic STroke and underlying AtriaL
fibrillation
ECG – electrocardiography
ELR – event loop recorder
ESVEA – excessive supraventricular ectopic activity
EMBRACE – 30-day Cardiac Event Monitor Belt for Recording
Atrial Fibrillation after a Cerebral Ischemic Event
ESUS – embolic stroke of uncertain source
HAS-BLED – Hypertension (that is, uncontrolled blood pressure),
Abnormal renal and liver function (1 point each), Stroke, Bleeding
tendency or predisposition, Labile INR, elderly (>65 years, high
frailty), Drugs (eg. concomitant aspirin or NSAIDs) and alcohol (1
point each)
HR – hazard ratio
ICD – implantable cardioverter-defibrillator
ILR – implantable/insertable loop recorder
IMPACT AF – Randomized trial to IMProve treatment with
AntiCoagulanTs in patients with Atrial Fibrillation
INR – international normalised ratio
LA – left atrium
LAA – left atrial appendage
MDCT – multi-detector row computed tomography
MOST – MOde Selection Trial
MRI – magnetic resonance imaging
NOACs – non-vitamin K antagonist oral anticoagulants
OAC – oral anticoagulation
OR – odds ratio
PPM – permanent pacemaker
PSC – premature supraventricular contraction
RM – remote monitoring
RR – relative risk
SAF – silent/asymptomatic AF
SAMe-TT2R2 – Sex (female), Age (<60 years), Medical history,
Treatment (interacting drugs, e.g. amiodarone for rhythm control),
Tobacco use (within 2 years) (doubled), Race (non-Caucasian)
(doubled)
SCAF – subclinical AF
SND – sinus node dysfunction
SOS AF – Stroke preventiOn Strategies based on Atrial Fibrillation
information from implanted devices
TE – thromboembolic / thromboembolism
TIA – transient ischaemic attack
TRENDS – The Relationship Between Daily Atrial Tachyarrhythmia
Burden From Implantable Device Diagnostics and Stroke
TTR – time in the therapeutic range
VKA – vitamin K antagonist
Table 1 Scientific rationale of recommendations
Scientific evidence that a treat-
ment or procedure is benefi-
cial and effective. Requires at
least one randomized trial, or
is supported by strong obser-
vational evidence and authors’
consensus.
Recommended/
indicated
General agreement and/or scien-
tific evidence favour the use-
fulness/efficacy of a treatment
or procedure. May be sup-
ported by randomized trials
that are, however, based on
small number of patients to
allow a green heart
recommendation.
May be
used or
recommended
Scientific evidence or general
agreement not to use or rec-
ommend a treatment or
procedure.
Should NOT
be used or
recommended
This categorization for our consensus document should not be considered as being
directly similar to that used for official society guideline recommendations which
apply a classification (I-III) and level of evidence (A, B, and C) to recommendations.
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Introduction
Among atrial tachyarrhythmias (AT), atrial fibrillation (AF) is the
most common sustained arrhythmia. Many patients with AT have no
symptoms during brief or even extended periods of the arrhythmia,
making detection in patients at risk for stroke challenging. Subclinical
atrial tachyarrhythmia and asymptomatic or silent atrial tachyarrhyth-
mia often precede the development of clinical AF. Clinical AF and
subclinical atrial fibrillation (SCAF) are associated with an increased
risk of thromboembolism. Indeed, in many cases, SCAF is discovered
only after complications such as ischaemic stroke or congestive heart
failure have occurred.
Subclinical AT can be detected by various cardiac monitoring
methods, including external surface monitoring (e.g. standard 12-lead
electrocardiogram, ambulatory Holter monitors, event monitors)
and by implantable cardiac devices (e.g. implantable cardiac loop re-
corders, dual-chamber permanent pacemakers (PPM), dual-chamber
implantable cardioverter-defibrillators (ICD), cardiac resynchroniza-
tion therapy (CRT) devices), many of which have remote monitoring
capabilities.
Current guidelines do not address in detail management of SCAF.1
There is therefore a need to provide expert recommendations for
professionals participating in the care of such patients. To address
this topic, a Task Force was convened by the European Heart
Rhythm Association (EHRA), with representation from the Heart
Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS)
and Sociedad LatinoAmericana de Estimulacion Cardiaca y
Electrofisiologia (SOLEACE), with the remit to comprehensively re-
view the published evidence available, and to publish a joint consen-
sus document on the management of patients with subclinical AT,
with up-to-date consensus recommendations for clinical practice.
This consensus document will address definitions, clinical importance,
implications and management of device-detected subclinical atrial
tachyarrhythmias, as well as current developments in the field.
Evidence review
Consensus statements are evidence-based, and derived primarily
from published data. In contrast with current systems of ranking level
of evidence, EHRA has opted for a simpler, perhaps, more user-
friendly system of ranking that should allow physicians to easily assess
current status of evidence and consequent guidance (Table 1). Thus,
a ‘green heart’ indicates a recommended statement or
recommended/indicated treatment or procedure and is based on at
least one randomized trial, or is supported by strong observational
evidence that it is beneficial and effective. A ‘yellow heart’ indicates
that general agreement and/or scientific evidence favouring a state-
ment or the usefulness/efficacy of a treatment or procedure may be
supported by randomized trials based on small number of patients or
not widely applicable. Treatment strategies for which there has been
scientific evidence that they are potentially harmful and should not be
used are indicated by a ‘red heart’. EHRA grading of consensus state-
ments does not have separate definitions of Level of Evidence. The
categorization used for consensus statements (used in consensus
documents) should not be considered as being directly similar to that
used for official society guideline recommendations which apply a
classification (I–III) and level of evidence (A, B and C) to recommen-
dations in official guidelines.
Relationships with industry and other
conflicts
It is an EHRA/ESC policy to sponsor position papers and guidelines
without commercial support, and all members volunteered their
time. Thus, all members of the writing group as well as reviewers
have disclosed any potential conflict of interest in detail, at the end of
this document.
Incidence and predictors of
device-detected subclinical atrial
tachyarrhythmias
The reported incidence of subclinical AT varies with the study design
(retrospective or prospective), underlying heart disease (sinus node
dysfunction (SND), atrioventricular block (AVB), or heart failure),
presence or absence of AF history, definition of atrial high rate epi-
sode (AHRE) duration, type of device detecting the AT, and the ob-
servation period.2–7
A retrospective study in SND/AVB patients without AF history
reported that the incidence of pacemaker-detected AHRE >_5 min
was 29% (77/262 patients) at a mean follow-up of 596 days (24%
at 1 year and 34% at 2 years); cumulative percentage of right ven-
tricular pacing >_50% was the only predictor of the occurrence of
AHREs.3 Another study reported that the incidence of
pacemaker-detected AF was 51.8% (173/334 patients without AF
history) over a mean follow-up of 52 months, and the patients
with subclinical AF were older and more likely to have a history
of clinical AF and larger left atrial volumes.4 The atrial diagnostics
ancillary study of the MOST (MOde Selection Trial) revealed that
160 (51.3%) of 312 patients with pacemakers implanted for sinus
node disease had at least one AHRE lasting at least 5 min at a
median follow-up of 27 months. Patients with AHREs were more
likely to have a history of supraventricular arrhythmias, AVB, use
of antiarrhythmic drug, and presence of heart failure than those
without AHRE.5
Overall, the incidence of subclinical AT/AF is 20% within 1 year
of follow-up, but there have been no consistent predictors of SCAF
in patients with PPMs and ICDs and without AF history.
Symptoms during atrial
fibrillation episodes
Patient’ perceptions of arrhythmia symptoms are highly variable: this
includes individual awareness of on-going tachyarrhythmia. Among
pacemaker patients who are known to experience symptoms due to
AF only17–21% of symptoms were actually correlated with an epi-
sode of AF.8,9 Asymptomatic AF is 12-fold more frequent than symp-
tomatic AF in patients with paroxysmal AF, when evaluated by use of
5-day Holter monitoring10; only 10% of episodes give rise to symp-
toms. In pacemaker patients with known AF, asymptomatic AF com-
prises 38–81% of all AF episodes.9,11 Among 114 patients with
documented AF episodes 5% of patients had only asymptomatic AF
episodes prior to pulmonary vein isolation on 7-day Holter monitor-
ing whereas 37% of patients had only asymptomatic AF 6 months
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after ablation, suggesting that the perception of symptoms changes
after catheter ablation.12
There is no evidence that asymptomatic AF patients have a dif-
ferent risk profile compared with symptomatic AF. Several pro-
spective trials are ongoing (Table 2).13–15 The presence of
symptoms will likely have little impact on clinical outcome, except
that it increases the probability of earlier diagnosis and appropriate
treatment.
Detection and targeted screening
for subclinical and silent
(asymptomatic) atrial
tachyarrhythmias in patients with
CIEDs and higher risk populations
Detection of subclinical AF in patients
with implanted permanent pacemakers,
ICDs, and CRT devices
The term SCAF has been used to describe atrial arrhythmia episodes
detected by cardiac implanted electronic devices (CIEDs). SCAF is
usually discovered incidentally during a routine evaluation of the
CIED, and has not caused any symptoms prompting the patient to
seek medical attention. Patients with CIEDs have an advantage over
cardiac patients who do not have a continuous arrhythmia monitor in
place because clinically silent arrhythmias can be detected.
Current evidence suggests that the prevalence of SCAF is consid-
erable among patients with implanted devices, and that the presence
of subclinical AF increases the risk of thromboembolism (TE).5–7 The
minimum duration of AF (or minimum AF burden) which confers this
increased TE risk is not precisely defined, but may be as brief as sev-
eral minutes to several hours. The advent of non-vitamin K antagonist
oral anticoagulants (NOACs), which offer the promise of improved
efficacy and safety profiles, may further widen the indication for oral
anticoagulation.13,14
Epidemiology of atrial fibrillation in patients with cardiac
implantable electronic devices
The prevalence of AF in patients with CIEDs is reported to range
from 30% to 60%.4–7,16–21 In early 2000s, two studies of patients with
pacemakers implanted for sinus node disease have reported atrial ar-
rhythmias in 50–68% of patients.5,16 More recently, Healey et al.4
have shown similar results: AF was detected during follow-up in
55% of unselected populations of patients with pacemakers which
exactly reproduced earlier findings.21
Studies specifically designed to exclude subgroups of patients
who may have had AF in the past (history of AF, history of oral
anticoagulation use, history of anti-arrhythmic drug use), have found
an incidence of newly detected SCAF in 30% of device patients.
For example, patients from the TRENDS (The Relationship
Between Daily Atrial Tachyarrhythmia Burden From Implantable
Device Diagnostics and Stroke) trial in 1368 patients who had no
prior history of AF, no previous stroke or transient ischaemic attack
(TIA) and no warfarin or antiarrhythmic drug use were analysed to
look for newly detected AF.6 Newly detected AF was defined as
device-detected AHRE lasting at least 5 min. Thirty percent of pa-
tients (416 patients) experienced newly detected AF. The incidence
of newly detected AF was consistent across patients with inter-
mediate (virtual CHADS2 score of 1) (30%), high (virtual CHADS2
score of 2) (31%), and very high (virtual CHADS2 score of >_3)
(31%) stroke risk factors (P = 0.92). (A virtual CHADS2 score is cal-
culated in a patient who has never previously had AF.) However, a
significant increase was seen in the proportion of patients having
days with >6 h of AT/AF as the virtual CHADS2 score increased;
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>6 hour (p=0.04)
Figure 1 Incidence of newly detected atrial fibrillation
(AHRE >5-min duration) in relation to the virtual CHADS2 score.
AHRE, atrial high rate episode; AF, atrial fibrillation; AT, atrial tachy-
cardia. Reproduced from reference5 with permission by Elsevier.
.................................................................................................
Table 3 Fact box on clinical significance of subclinical
and silent/asymptomatic atrial fibrillation
Facts Supporting
references
• Patients with symptoms have a higher
probability of earlier diagnosis and
thereby receive evaluation about relevant
medical treatment compared with non-
symptomatic patients
13–15
• The vast majority of AF episodes are
asymptomatic
8–11
• At this time asymptomatic AF should be
treated as symptomatic AF with regard to
oral anticoagulation
13–15
• The thromboembolic risk related to dif-
ferent durations of AF episodes is incom-
pletely understood
13–15
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12%, 15%, and 18% for intermediate, high, and very high risk, re-
spectively; P = 0.04 (Figure 1).
In another analysis from the TRENDS trial, the incidence of newly
detected AF was analysed in patients (319 patients) with a prior his-
tory of stroke or TIA.17 Patients (n = 156) with a documented history
of AF, warfarin use, or antiarrhythmic drug use were excluded from
analysis. Newly detected AF (AHRE lasting at least 5 min) was identi-
fied by the implantable device in 45 of 163 patients (28%) over a
mean follow-up of 1.1 years.
In the ASSERT (ASymptomatic atrial fibrillation and Stroke
Evaluation in pacemaker patients and atrial fibrillation Reduction atrial
pacing Trial), a study of 2580 patients with a history of hypertension
and no prior history of AF, SCAF (defined as lasting at least 6 min in
duration) was detected at least once in 35% of the patients over a
mean follow-up of 2.5 years.7 Taken together, these two large studies
show remarkably similar results: in patients with CIEDs, stroke risk
factors, and no prior history of AF (regardless of TE history), SCAF
can be identified in30% of patients. Selected trials that determined
the incidence of device-detected AF are outlined in Table 4.
Thromboembolic risk of subclinical atrial fibrillation in
the cardiac implantable electronic devices population
The major studies regarding the thromboembolic risk of sub-clinical
device-detected AHRE in general populations of patients with
....................................................................................................................................................................................................................
Table 5 Summary of studies on atrial fibrillation detected by CIEDs and thromboembolic risk
Year Trial Number
of patients
Duration of
follow-up
Atrial rate
cut-off
AF burden
threshold
Hazard ratio
for TE event
TE event rate
(below vs. above AF
burden threshold)
2003 Ancillary MOST5 312 27 months (median) >220 bpm 5 min 6.7 (P=0.020) 3.2% overall (1.3% vs. 5%)
2005 Italian AT500 Registry18 725 22 months (median) >174 bpm 24 h 3.1 (P=0.044) 1.2% annual rate
2009 Botto et al.19 568 1 year (mean) >174 bpm CHADS2þAF
burden
n/a 2.5% overall (0.8% vs. 5%)
2009 TRENDS20 2486 1.4 years (mean) >175 bpm 5.5 h 2.2 (P=0.060) 1.2% overall (1.1% vs. 2.4%)
2012 Home Monitor CRT22 560 370 days (median) >180 bpm 3.8 h 9.4 (P=0.006) 2.0% overall
2012 ASSERT7 2580 2.5 years (mean) >190 bpm 6 min 2.5 (P=0.007) (0.69% vs. 1.69%)
2014 SOS AF23 10016 2 years (median) >175 bpm 1 h 2.11 (P=0.008) 0.39% per year
Overall
AF, atrial fibrillation; bpm, beats per minute; CIED, cardiac implantable electronic device; CRT, cardiac resynchronization therapy; TE, thromboembolic; SOS AF, Stroke
preventiOn Strategies based on Atrial Fibrillation information from implanted devices. Other abbreviations as in Table 4.
....................................................................................................................................................................................................................
Table 4 Incidence of atrial fibrillation in the implanted device population
Year Study Device Indication Clinical Profile of Patients Follow-up Incidence of AF
2002 Gillis et al.16 PPMs for sinus node disease All 718±383 days 157/231 (68%)
2003 MOST5 PPMs for sinus node disease All median 27 months 156/312 (50%)
2006 BEATS21 PPMs for all indications All Prospective, 12 months 137/254 (54%)
2010 TRENDS17 PPMs and ICDs History of prior stroke Mean 1.4 years 45/163 (28%)
All indications No history of AF
No OAC use
>_1 stroke risk factor
2012 TRENDS6 PPMs and ICDs No history of prior stroke 1.1±0.7 years 416/1368 (30%)
All indications No history of AF
No OAC use
>_1 stroke risk factor
2012 ASSERT7 PPMs and ICDs History of hypertension 2.5 years 895/2580 (34.7%)
All indications No history of AF
No OAC use
2013 Healey et al.4 PPMs All Single center retrospective 246/445 (55.3%)
All indications
AF, atrial fibrillation; ICD, implantable cardioverter-defibrillator; OAC, oral anticoagulation; PPM, permanent pacemaker; ASSERT, ASymptomatic atrial fibrillation and Stroke
Evaluation in pacemaker patients and atrial fibrillation Reduction atrial pacing Trial; BEATS, Balanced Evaluation of Atrial Tachyarrhythmias in Stimulated patients; MOST, MOde
Selection Trial; TRENDS, The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke.
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implanted pacemakers, defibrillators, and CRT are summarized in
Table 5.5,7,18–20,22,23. All show increases in stroke rate associated with
device-detected AF episodes. A minimum of 5 min of AF was first
found to have clinical relevance in 2003.5 Alternative burden cut-
points have been explored over the subsequent 10 years, ranging from
5 min to 24 h, coming back nearly full circle to the clinical significance of
6 min of AHRE burden in 2012.7 In all of these studies, the AF thresh-
old cut-points were either arbitrarily chosen, or were the results of
the data itself (i.e. median values). Thus, there is still uncertainty regard-
ing the minimum duration of device-detected AF that increases TE risk.
Temporal proximity of device-detected AF to stroke events
There does not seem to be a close temporal relationship of device-
detected atrial arrhythmias to the occurrence of strokes, despite the
fact that patients who have AHREs are at a significantly increased risk
of stroke. Several studies have highlighted this point and are outlined in
Table 6.23–26 In the majority of patients (73–94%) there was no AF on
the device recordings in the 30 days prior to the TE events. These data
imply that, in the majority of device patients with AHREs and thrombo-
embolic events, the mechanism of stroke may not be related to the AF
episodes. It does not seem to matter if the AF episode is proximal to
the stroke event,23 and risk seems to be increased by relatively brief
Table 7 Causes for inappropriate atrial fibrillation detection and solutions by device programming7,36,37
False negative detection (AF not diagnosed by tde device)
True atrial undersensing (AF not sensed due to small signals) Increase atrial sensitivity (recommended setting: bipolar, 0.2–0.3 mV)
Functional atrial undersensing (AF potentials coincide with atrial blank-
ing times)
Only important in atrial flutter; (i) limit upper tracking rate
to <_ 110 bpm if clinically feasible, (ii) activate specific atrial flutter
detection algorithms
False positive detection (oversensed signals mistaken for AF)
Ventricular farfield oversensing in the atrium Prolong postventricular atrial blanking time (recommended: 100–
150 ms)
Myopotential oversensing Bipolar sensing setting; reduce sensitivity
Electromagnetic interference, lead failure Activate noise reaction; lead revision
Ineffective atrial pacing (repetitive non-reentrant VA synchrony) Reduce or deactivate sensor reactivity in rate-responsive pacing;
shorten paced AV delay, activate non-competitive atrial pacing,
inactivate AF suppression algorithm
Abbreviations. AF, atrial fibrillartion; AV, atrioventricular; VA ventriculoatrial.
....................................................................................................................................................................................................................
Table 6 Temporal relationship of device-detected atrial fibrillation to thromboembolic events
Year Trial Number
of patients
with TE event
Definition of
AF episode
Any AF detected
prior to TE event
AF detected
only after
TE event
No AF in
30 days prior
to TE event
Any AF in
30 days prior
to TE event
2011 TRENDS24 40 5 min 20/40 (50%) 6/40 (15%) 29/40 (73%) 11/40 (27%)
2014 ASSERT25 51 6 min 18/51 (35%) 8/51 (16%) 47/51 (92%) 4/51 (8%)
2014 IMPACT AF26 69 36/48 atrial beats
>_200 bpm
20/69 (29%) 9/69 (13%) 65/69 (94%) 4/69 (6%)
AF, atrial fibrillation; bpm, beats per minute; TE, thromboembolic; IMPACT AF, Randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation.
Other abbreviations as in Table 4.
.................................................................................................
Table 8 Recommendations and fact box for the man-
agement of device-detected atrial arrhythmias
Recommendations Class Supporting
references
If available, review stored intracar-
diac electrograms to confirm
diagnosis and exclude artifact or
reduce the effect of oversensing/
undersensing by automated algo-
rithms is recommended; solutions
to correct inappropriate AF de-
tection are provided in Table 7
6, 36, 37
Facts
The presence or absence of symp-
toms has no bearing on determin-
ing the need for anticoagulation.
13–15, 18–20,
22, 23
AF, atrial fibrillation.
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AF episodes.27,28 What does seem to be consistent is the finding that
the appearance of new AHREs increases thromboembolic event rates.
Therefore, short episodes of newly detected AF may represent rather
a marker for an 2.5-fold risk of stroke but not the immediate cause
of intracardiac thrombus formation and cardioembolic stroke.
Detection of atrial fibrillation in cardiac implantable
electronic devices by remote monitoring
The capability of remote monitoring (RM) to detect AF has been
consistently demonstrated by several observational29,30 and random-
ized trials.31,32 In the worldwide Home Monitoring database
analysis,33 3 004 763 transmissions were sent by 11 624 patients with
pacemakers, ICDs, and CRT devices. AF was responsible for >60% of
alerts in pacemakers and CRT-D devices, and for nearly 10% of alerts
in dual-chamber ICDs. The rate of false-positive alerts was low—
86% were disease-related, 11%—system-related and 3%—device
programming-related.
Approximately 90% of AF episodes triggering alerts are asymp-
tomatic.30 Even when an inductive remote monitoring system (with-
out automatic alerts) is studied, RM performed better than standard
follow-up in pacemaker patients for detection of AF.34,35 Compared
to standard scheduled follow-up, detection of AF occurs 1–5 months
earlier with RM.
Device programming and choice of atrial lead for reliable
atrial fibrillation detection
An implanted atrial lead is ideal to reliably detect AF, it is superior to
the surface ECG that may mistake irregular RR intervals due to fre-
quent premature atrial beats for AF, and unaffected by the regular RR
intervals during AF in patients with AVB. However, even in automatic
detection of AF by devices, the causes of false positive and false nega-
tive detections must be known to avoid misinterpretation of stored
data (Table 7). For reliable AF detection by devices, a bipolar atrial
lead (preferably with short bipole spacing) is required. A high atrial
sensitivity is necessary to avoid intermittent undersensing of AF that
can result in inappropriate detection of persistent AF as multiple
short episodes. Ventricular farfield oversensing can be avoided by ad-
justing the postventricular atrial blanking time as shown in two
randomized prospective trials.7,36 Some specific forms of inappropri-
ate AF detection by implantable devices with atrial leads should be
known37 to avoid misinterpretation and wrong treatment guided by
device memory. It is also worth mentioning that cut-off values for
AHRE rate and duration affects the false-positive results: longer dur-
ation of AHRE >190 beats/min >6 h reduces false-positive results as
compared to >6-min duration.38
The presence of AF is associated with an almost five-fold increased
risk of stroke.39 However, the precise role that SCAF plays in raising
the risk of stroke is less well understood. Further studies need to ad-
dress whether AF is merely a marker for atrial fibrotic disease,1 which
predisposes a patient to an increased risk of stroke, or patient’s risk
of stroke increases primarily during and shortly following the
.................................................................................................
Table 10 Recommendations for treatment of sub-
clinical atrial fibrillation with oral anticoagulation
CHA2DS2-
VASc score
Duration of AHRE Recommendation
>_2 >5.5 h (lower duration if mul-
tiple stroke risk factors are
present)*
1 (male) or 2
(female)
>5.5 h*
*Data suggests risk is similarly increased by a mere 5 min.
AHRE, atrial high rate episode.
.................................................................................................
Table 9 Recommendations for treatment of sub-clin-
ical AF with oral anticoagulation
Recommendations Class
Assessment of the patient’s stroke risk using
the CHA2DS2-VASc score is
recommended
No antithrombotic therapy for any patient with
CHA2DS2-VASc score of 0 in males or 1 in fe-
males, irrespective of AHRE, is recommended
For patients with two additional CHA2DS2-VASc
risk factors (ie. >_2 in males, >_3 in females) oral
anticoagulation is recommended for AF burden
>5.5 h/day (if there are no contraindications).
Lower duration may merit OAC if multiple risk
factors are present.
For effective stroke prevention in patients with
CHA2DS2-VASc score >_2, oral anticoagulation,
whether with well controlled vitamin K antag-
onist (VKA) with a time in therapeutic range
>70%, or with a non-VKA oral anticoagulant
(NOAC, either dabigatran, rivaroxaban, apixa-
ban or edoxaban) is recommended
Consider oral anticoagulation for AF burden (lon-
gest total duration of AF on any given day)
of > 5.5 h in patients with 1 additional
CHA2DS2-VASc risk factor (ie. score=1 in
males or = 2 in females)
Recognize that the data suggests risk is similarly
increased by a mere 5-min episode, but it is
reasonable to see a patient with only a single 5-
min episode again in follow-up to observe their
AF burden over time before committing them
to life-long oral anticoagulation.
Bleeding risk should be assessed using validated
scores, such as the HAS-BLED score.
 Patients at high risk (score>_3) should be
identified for more regular review and fol-
low-up, and the reversible bleeding risk fac-
tors addressed.
 A high HAS-BLED score is not a reason to
withhold anticoagulation.
AF, atrial fibrillation; AHRE, atrial high rate episode; OAC, oral anticoagulation.
Device-detected subclinical atrial tachyarrhythmias : EHRA consensus document 1563
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
T
ab
le
1
1
A
m
b
u
la
to
ry
H
o
lt
e
r
m
o
n
it
o
ri
n
g
in
e
v
a
lu
a
ti
o
n
o
f
si
le
n
t/
a
sy
m
p
to
m
a
ti
c
a
tr
ia
l
ta
c
h
y
a
rr
h
y
th
m
ia
s
in
h
ig
h
-r
is
k
p
o
p
u
la
ti
o
n
s
S
tu
d
y
D
e
si
g
n
P
o
p
u
la
ti
o
n
E
C
G
m
o
n
it
o
ri
n
g
ty
p
e
s/
d
u
ra
ti
o
n
F
o
ll
o
w
-
u
p
A
F
/E
S
V
E
A
O
u
tc
o
m
e
s
R
is
k
/D
ia
g
n
o
st
ic
v
a
lu
e
(9
5
%
C
I)
Ex
ce
ss
iv
e
su
pr
av
en
tr
ic
ul
ar
ec
to
pi
c
ac
tiv
ity
Bi
ni
ci
et
al
.48
C
op
en
ha
ge
n
H
ol
te
r
St
ud
y
Po
pu
la
tio
n
co
ho
rt
67
8
he
al
th
y
m
en
an
d
w
om
en
w
ith
ou
t
C
V
D
,A
F
or
st
ro
ke
,
55
–7
5
y
48
h
H
M
ES
V
EA
—
>_
30
PC
S/
h
or
PS
C
ru
ns
>
20
be
at
s
6.
3
y
ES
V
EA
70
ep
is
od
es
,
PS
C
ru
ns
42
ep
is
od
es
ES
V
EA
(þ
)
vs
.
ES
V
EA
(-
)
A
F—
12
.8
/1
00
0
py
vs
.4
.3
/
10
00
py
,P
=
0.
00
8
St
ro
ke
—
18
.8
/1
00
0
py
vs
.
4.
9/
10
00
py
,P
=
0.
00
02
M
or
ta
lit
y—
37
.2
/1
00
0
py
vs
.1
8.
9/
10
00
py
,
P=
0.
00
5
D
ea
th
or
St
ro
ke
a H
R
1.
6
(1
.0
3–
2.
06
),
P=
0.
03
6
St
ro
ke
ad
m
is
si
on
b
H
R
2.
37
(1
.0
2–
5.
5)
,
P=
0.
04
4
A
F
ad
m
is
si
on
s–
cH
R
2.
73
(1
.0
7–
6.
96
),
P=
0.
03
5
La
rs
en
et
al
.43
C
op
en
ha
ge
n
H
ol
te
r
St
ud
y
Po
pu
la
tio
n
co
ho
rt
67
8
he
al
th
y
m
en
an
d
w
om
en
w
/o
C
V
D
,A
F
or
st
ro
ke
55
–7
5
y
48
-h
H
M
14
.4
y
ES
V
EA
(þ
)
99
(1
4.
6%
)
ES
V
EA
(-
)
57
9
(8
5.
4%
)
Ex
cl
ud
in
g
A
F
ca
se
s
Is
ch
em
ic
st
ro
ke
19
.9
/1
00
0
py
vs
.
7.
2/
10
00
py
,
P=
0.
00
01
Is
ch
em
ic
st
ro
ke
d
H
R
1.
96
(1
.1
–3
.4
9)
,
P=
0.
02
ES
V
EA
(þ
)
C
H
A
2
D
S 2
-
V
A
Sc
>_
2
24
.1
%
st
ro
ke
ev
en
ts
pe
r
10
00
py
ES
V
EA
(-
)
C
H
A
2
D
S 2
-
V
A
Sc
>_
2
9.
9%
st
ro
ke
ev
en
ts
pe
r
10
00
py
D
ew
la
nd
et
al
.48
C
ar
di
ov
as
cu
la
r
H
ea
lth
St
ud
y
Pr
os
pe
ct
iv
e
co
ho
rt
12
60
su
bj
ec
ts
w
/o
A
F,
>
65
y
24
h
H
M
13
y
A
F—
27
%
R
is
k—
do
ub
lin
g
of
ho
ur
ly
PS
C
In
ci
de
nt
A
F—
H
R
1.
17
(1
.1
3–
1.
22
),
<
0.
00
1
M
or
ta
lit
y—
H
R
1.
06
(1
.0
3–
1.
09
),
<
0.
00
1
En
gs
tr
om
et
al
.50
‘M
en
bo
rn
in
19
14
’
Pr
os
pe
ct
iv
e
co
ho
rt
40
2
m
en
68
y
w
/o
M
Io
r
st
ro
ke
24
-h
H
M
A
F,
PS
C
>
21
8/
h
14
y
St
ro
ke
:
N
o
PS
C
/N
o
A
F—
11
.6
/1
00
0
py
,F
re
qu
en
t
PS
C
—
19
.5
/1
00
0
py
,A
F—
34
.5
/1
00
0
py
,
P=
0.
00
7
R
is
k
of
st
ro
ke
:R
ef
er
en
ce
—
N
o
A
F
or
PS
C
e P
SC
H
R
1.
9
(1
.0
2–
3.
4)
,P
=
0.
04
G
la
ds
to
ne
et
al
.51
EM
BR
A
C
E
tr
ia
l
R
C
T
In
te
rv
en
tio
n
ar
m
an
al
ys
is
23
7
pt
s
w
ith
C
S
or
T
IA
w
/o
A
F
>
55
y
Ba
se
lin
e
24
-h
H
M
30
-d
ay
EL
R
2
y
PS
C
/2
4
h
(IQ
R
)
A
F—
62
9
(1
42
–1
97
3)
w
/o
A
F—
45
(1
4–
25
0)
,
P<
0.
00
1
SA
F
de
te
ct
io
n
ra
te
pr
ob
ab
ili
ty
R
ef
er
en
ce
90
-d
ay
A
F—
16
%
PS
C
10
0/
24
h—
<
9%
PS
C
10
0–
49
9/
24
h—
9–
24
%
PS
C
50
0–
99
9/
24
h—
25
–3
7%
PS
C
10
00
–1
49
9/
24
h—
37
–4
0%
PS
C
>
15
00
/2
4
h—
40
%
Co
nt
in
ue
d
1564 B. Gorenek et al.
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
T
ab
le
1
1
C
o
n
ti
n
u
e
d
S
tu
d
y
D
e
si
g
n
P
o
p
u
la
ti
o
n
E
C
G
m
o
n
it
o
ri
n
g
ty
p
e
s/
d
u
ra
ti
o
n
F
o
ll
o
w
-
u
p
A
F
/E
S
V
E
A
O
u
tc
o
m
e
s
R
is
k
/D
ia
g
n
o
st
ic
v
a
lu
e
(9
5
%
C
I)
A
tr
ia
lfi
br
ill
at
io
n
Sa
lv
at
or
ie
ta
l.5
2
Pe
ru
gi
a
G
en
er
al
Pr
ac
tit
io
ne
r
St
ud
y
Pr
os
pe
ct
iv
e
co
ho
rt
30
9
pt
s
w
ith
H
T
>
65
y
27
4—
H
M
48
h
H
M
SA
F
10
%
(6
.4
–3
.5
%
),
ES
V
EA
20
%
(1
5.
3–
4.
7%
)
R
is
k
fa
ct
or
s
fo
r:
SA
F—
ag
e
O
R
1.
12
(1
.0
2–
1.
24
),
P=
0.
02
1
ES
V
EA
—
ag
e
O
R
-(
1.
02
–1
.1
2)
,P
=
0.
00
9
M
ar
fe
lla
et
al
.53
Pr
os
pe
ct
iv
e
ca
se
-
co
nt
ro
lle
d
C
ro
ss
-s
ec
tio
na
l
ar
m
46
4
D
M
pt
s
24
0
he
al
th
y
co
nt
ro
l
su
bj
ec
ts
48
h
H
M
—
qu
ar
te
rl
y
A
F
<
48
h
du
ra
tio
n
37
m
C
ro
ss
-s
ec
tio
na
l:
D
M
vs
.C
on
tr
ol
s
SA
F—
11
%
vs
.1
.6
%
,P
<
0.
00
01
Pr
os
pe
ct
iv
e:
St
ro
ke
ra
te
:S
A
F
D
M
vs
.D
M
:
1s
t
y—
3.
8%
vs
.1
.4
%
2n
d
y—
6.
2%
vs
.2
.2
%
f S
A
F
as
so
ci
at
io
n:
SC
IO
R
4.
44
1
(2
.4
18
–
8.
15
7)
LA
D
O
R
2.
66
7
(1
.4
76
–
4.
82
1)
SB
P
O
R
1.
03
(1
.0
10
–
1.
05
0)
D
M
du
ra
tio
n
O
R
1.
07
5
(1
.0
02
–1
.1
54
)
R
is
k
of
st
ro
ke
:
SA
F
H
R
4.
6
(2
.7
–9
.1
)
SB
P
H
R
1.
7
(1
.0
2–
2.
92
)
SC
IH
R
3.
1
(1
.3
–7
.1
)
St
am
bo
ul
et
al
.42
Pr
os
pe
ct
iv
e
co
ho
rt
73
7
M
Ip
ts
C
on
tin
uo
us
au
to
-
m
at
ed
48
-h
EC
G
m
on
.
In
-h
os
pi
ta
l
1
y
A
F—
14
%
SA
F—
4%
SA
F
vs
.n
o
A
F
H
F
ho
sp
.
6.
6%
vs
.1
.3
%
,P
<
0.
00
1
C
V
de
at
h
5.
7%
vs
.2
.0
%
,
P<
0.
00
1
SA
F
vs
.n
o
A
F
C
V
de
at
h
or
H
F
ho
sp
.
O
R
2.
23
6
(9
5%
C
I1
.0
15
–
4.
92
6)
P=
0.
04
6
St
am
bo
ul
et
al
.54
Pr
os
pe
ct
iv
e
co
ho
rt
84
9
M
Ip
ts
C
on
tin
uo
us
au
to
-
m
at
ed
48
-h
EC
G
m
on
ito
ri
ng
In
-h
os
pi
ta
l
In
-h
os
pi
ta
l
SA
F—
16
%
SA
F
vs
.N
o
A
F
H
F
41
.8
%
vs
.2
1%
,
P<
0.
00
01
D
ea
th
10
.4
%
vs
.1
.3
%
,
P<
0.
00
01
Pr
ed
ic
to
rs
of
m
or
ta
lit
y:
SA
F—
O
R
3.
65
(1
.4
4–
9.
23
),
P=
0.
00
6
Pr
ed
ic
to
rs
of
SA
F
H
is
to
ry
of
A
F
O
R
3.
07
(1
.3
8–
6.
82
),
P=
0.
00
6
A
ge
,p
er
/y
1.
06
(1
.0
4–
1.
07
),
P<
0.
00
1
LA
ar
ea
pe
r
cm
2
/m
2
1.
11
(1
.0
4–
1.
18
),
P=
0.
00
2
Co
nt
in
ue
d
Device-detected subclinical atrial tachyarrhythmias : EHRA consensus document 1565
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
T
ab
le
1
1
C
o
n
ti
n
u
e
d
S
tu
d
y
D
e
si
g
n
P
o
p
u
la
ti
o
n
E
C
G
m
o
n
it
o
ri
n
g
ty
p
e
s/
d
u
ra
ti
o
n
F
o
ll
o
w
-
u
p
A
F
/E
S
V
E
A
O
u
tc
o
m
e
s
R
is
k
/D
ia
g
n
o
st
ic
v
a
lu
e
(9
5
%
C
I)
G
ro
nd
et
al
.56
Pr
os
pe
ct
iv
e
co
-
ho
rt
st
ud
y
11
37
st
ro
ke
T
IA
pt
s
67
y
w
/o
kn
ow
n
A
F
24
h
H
M
72
h
H
M
SA
F
24
h
H
M
:
2.
6%
(1
.5
–3
.7
%
)
72
h
H
M
:
4.
3%
(3
.4
–5
.2
%
)
Pr
ed
ic
to
rs
of
SA
F:
A
dv
an
ce
d
ag
e
O
R
1.
07
6
(1
.0
42
–1
.1
11
,P
<
0.
00
01
)
M
ild
-m
od
er
at
e
vs
.s
ev
er
e
ne
ur
ol
og
ic
al
de
fic
it
O
R
0.
26
1
(0
.1
34
–0
.5
11
)
T
IA
pt
s:
Pr
es
en
ce
of
is
ch
em
ic
le
si
on
on
M
R
I
O
R
5.
43
9
(1
.2
76
–2
3.
18
11
)
H
in
dr
ic
ks
et
al
.12
Pr
os
pe
ct
iv
e
C
oh
or
t
St
ud
y
11
4
pt
s
U
nd
er
go
in
g
C
A
of
A
F
7-
da
y
H
M
Be
fo
re
C
A
A
ft
er
C
A
—
3,
6,
12
m
12
m
A
sy
m
pt
om
at
ic
A
F
Be
fo
re
C
A
—
5%
,A
ft
er
C
A
—
3
m
—
38
%
,P
=
0.
02
1,
6
m
—
37
%
,P
=
0.
02
1,
12
m
—
36
%
,P
<
0.
05
C
ho
e
et
al
.57
C
R
Y
ST
A
L-
A
F
R
C
T
16
8
pa
tie
nt
s
w
ith
C
S
or
T
IA
IC
M
an
d
si
m
ul
at
ed
m
on
ito
ri
ng
Si
ng
le
H
M
:2
4
h,
48
h,
7
da
ys
;Q
ua
rt
er
ly
:2
4
h,
48
h,
7
da
ys
;M
on
th
ly
—
24
h
an
d
30
da
ys
EM
Se
ns
iti
vi
ty
:
Si
ng
le
H
M
vs
.E
M
24
h—
1.
3%
,3
0
da
ys
EM
—
22
.8
%
,N
PV
—
ra
ng
e
82
.3
–8
5.
6%
Pe
ri
od
ic
al
:Q
ua
rt
er
ly
H
M
24
h—
3.
1%
,7
da
ys
—
20
.8
%
,N
PV
—
ra
ng
e
82
.6
–8
5.
3%
D
ag
re
s
et
al
.59
C
oh
or
t
21
5
pt
s
af
te
r
C
A
of
A
F
56
y
7
da
ys
H
M
6
m
af
te
r
C
A
of
A
F
O
ve
ra
ll
A
F
re
cu
rr
en
ce
7
da
ys
H
M
—
64
pt
s
(3
0%
)
R
ec
ur
re
nc
e
ra
te
s
de
te
ct
ed
ac
co
rd
in
g
to
th
e
le
ng
th
of
re
co
rd
in
g:
24
h—
59
%
,P
<
0.
00
1,
48
h—
67
%
,P
<
0.
00
1,
72
h—
80
%
,P
<
0.
00
1,
4
da
ys
—
91
%
P=
0.
04
1,
5
da
ys
—
91
%
P=
0.
04
1,
6
da
ys
—
95
%
P=
0.
24
2
of
10
0%
7
da
ys
H
M
Sp
os
at
o
et
al
.63
M
et
a-
an
al
ys
is
50
st
ud
ie
s
11
65
8
pt
s
w
ith
st
ro
ke
or
T
IA
w
ith
N
D
A
F
Ph
as
es
:
(1
)
ER
—
EC
G
(2
)
In
-h
os
pi
ta
l—
se
ri
al
EC
G
,C
EM
,T
M
,H
M
(3
)
1s
t
am
b
pe
ri
od
—
A
m
bu
la
to
ry
H
M
(4
)
2n
d
am
b
pe
ri
od
—
M
ob
ile
ou
tp
at
ie
nt
T
M
,
EL
R
,I
LR
Ph
as
e
1:
EC
G
in
ER
—
7.
7%
Ph
as
e
2:
se
ri
al
EC
G
—
5.
6%
,C
EM
—
7.
0%
,T
M
—
4.
1%
,H
M
—
4.
5%
,o
ve
ra
ll
ph
as
e
2–
5.
1%
Ph
as
e
3:
A
m
bu
la
to
ry
H
M
(1
-
to
7-
da
y
m
on
ito
ri
ng
)
10
.7
%
*,
**
Ph
as
e
4:
m
ob
ile
ou
t-
pa
tie
nt
T
M
—
15
.3
%
,E
LR
—
16
.2
%
,I
LR
—
16
.9
%
,O
ve
ra
ll
ph
as
e
4—
16
.9
%
,
O
ve
ra
ll—
23
.7
%
(1
7.
2–
31
.0
)
*P
=
0.
04
7
vs
.p
ha
se
2
**
P=
0.
03
7
vs
.i
n-
ho
sp
ita
lH
M
A
F,
at
ri
al
fib
ri
lla
tio
n;
A
T
,a
tr
ia
lt
ac
hy
ca
rd
ia
;B
M
I,
bo
dy
m
as
s
in
de
x;
C
EM
,c
on
tin
uo
us
st
ro
ke
un
it
el
ec
tr
oc
ar
di
og
ra
ph
ic
m
on
ito
ri
ng
;C
R
Y
ST
A
L,
C
R
Y
pt
og
en
ic
ST
ro
ke
an
d
un
de
rl
yi
ng
A
tr
ia
L
fib
ri
lla
tio
n;
C
S,
cr
yp
to
ge
ni
c
st
ro
ke
;C
V
,c
ar
di
ov
as
cu
la
r;
d,
da
ys
;D
BP
,d
ia
st
ol
ic
bl
oo
d
pr
es
su
re
;D
M
,d
ia
be
te
s;
EC
G
,e
le
ct
ro
ca
rd
io
gr
am
;E
LR
,e
ve
nt
lo
op
re
co
rd
er
;E
M
BR
A
C
E,
30
-d
ay
C
ar
di
ac
Ev
en
t
M
on
ito
r
Be
lt
fo
r
R
ec
or
di
ng
A
tr
ia
lF
ib
ri
lla
tio
n
af
te
r
a
C
er
eb
ra
lI
sc
he
m
ic
Ev
en
t;
ES
V
EA
,e
xc
es
si
ve
su
pr
av
en
tr
ic
ul
ar
ec
to
pi
c
ac
tiv
ity
;h
,h
ou
rs
;H
M
,H
ol
te
r
m
on
ito
ri
ng
;H
R
,h
az
ar
d
ra
tio
;H
T
,h
yp
er
te
ns
io
n;
IL
R
,i
m
pl
an
ta
bl
e/
in
se
rt
ab
le
lo
op
re
co
rd
er
;I
Q
R
,i
nt
er
qu
ar
til
e
ra
ng
e;
M
I,
m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
m
,m
on
th
s;
m
on
.,
m
on
ito
ri
ng
;N
D
A
F,
ne
w
ly
di
ag
no
se
d
A
F;
N
PV
,n
eg
at
iv
e
pr
ed
ic
tiv
e
va
lu
e;
O
R
,o
dd
s
ra
tio
;P
SC
,p
re
m
at
ur
e
su
pr
av
en
tr
ic
ul
ar
co
nt
ra
ct
io
n;
PP
V
,p
os
iti
ve
pr
ed
ic
tiv
e
va
lu
e;
R
C
T
,r
an
do
m
iz
ed
co
nt
ro
lle
d
st
ud
y;
SA
F,
si
le
nt
A
F;
SB
P,
sy
st
ol
ic
bl
oo
d
pr
es
su
re
;S
C
I,
si
le
nt
ce
re
br
al
in
fa
rc
t;
T
M
,t
el
em
et
ry
;y
,y
ea
rs
.
a A
dj
us
te
d
fo
r
sm
ok
in
g,
SB
P,
D
M
,c
ho
le
st
er
ol
,a
ge
an
d
se
x;
b
ad
ju
st
ed
ag
e,
se
x,
SB
P,
BM
I,
D
M
an
d
sm
ok
in
g;
c a
dj
us
te
d
fo
r
ag
e
an
d
se
x;
d
ad
ju
st
ed
fo
r
ag
e,
se
x,
sm
ok
in
g,
SB
P,
D
M
,B
M
I,
ch
ol
es
te
ro
l;
e a
dj
us
te
d
fo
r
SB
P,
D
M
,s
m
ok
in
g,
an
gi
na
pe
ct
or
is
;
f a
dj
us
te
d
fo
r
se
x,
BM
I,
D
BP
,D
M
du
ra
tio
n,
H
b1
A
c,
hy
pe
rl
ip
id
em
ia
.
1566 B. Gorenek et al.
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
occurrence of AF; and whether a single episode of AF lasting 5 min is
a sufficient indication for life-long anticoagulation. Until larger trials or
registries are conducted, it is important to follow established treat-
ment recommendations regarding oral anticoagulation (Tables 9
and 10), given the risk of fatal or disabling strokes if left untreated.
Whether this suggested approach to therapy will have a net bene-
fit in reducing TE events remains to be determined.
Ambulatory Holter monitoring to detect
atrial tachyarrhythmias
Current evidence on the role of Holter monitoring in screening for
subclinical arrhythmias is limited. Several observational cohort stud-
ies demonstrated an association of subclinical AT with increased risk
of stroke and mortality in high-risk populations (Table 11).7,40–43 The
efficacy of detection of SCAF by monitoring devices depends on the
duration and method of ECG monitoring: 24-h Holter monitoring
has moderate sensitivity (44–66%) compared to event recorders and
CIEDs (sensitivity—91%).44 Current guidelines on management of
patients with AF recommend Holter monitoring in cases when the
arrhythmia type is unknown and for monitoring efficacy of rate con-
trol.45,46 In clinical practice, Holter monitoring of variable duration of
up to 7 days is also used for detection of asymptomatic AF in popula-
tions undergoing a rhythm control strategy, including post-ablation.47
Excessive supraventricular ectopic activity (ESVEA) is associated
with risk of incident AF [>_30 premature supraventricular contrac-
tions (PSC)/hour or episode of PSC runs >_20 beats),48 stroke (>_729
PSC/24 h or episode of PSC runs >_20 beats),43 and mortality in se-
lected populations depending on the frequency of PSC on Holter
monitoring.49–51 It was an independent predictor of stroke and inci-
dent AF admissions in a middle-aged population,47 and in combin-
ation with CHA2DS2-VASc score >_2 yielded 24.1% stroke events per
1000 patient years compared to 9.9% of stroke events per 1000 pa-
tient years in those CHA2DS2-VASc score >_2 and without ESVEA.
43
Doubling of hourly rate of PSC increased the risk of subsequent AF,
cardiovascular and overall mortality in elderly (>65 years old)49 and
frequent PSC doubled the risk of stroke in elderly men with or with-
out hypertension.50 In a substudy of the EMBRACE (30-day Cardiac
Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral
Ischemic Event) trial,51 ESVEA detected by 24-h Holter monitoring
was a predictor of AF developing after cryptogenic stroke and pre-
dicted detection of AF by 30-day event monitor.
Silent AF (SAF) rates vary between 1.5% and 14% in high-risk
populations, depending on type and duration of monitoring.12,41,52–59
SAF was associated with older age and presence of ESVEA on 48-h
Holter monitoring in patients with hypertension.52 Patients with dia-
betes and SAF were more likely to have silent cerebral infarct (lacu-
nar infarct of <15 mm on magnetic resonance imaging), dilatation of
left atrium, high blood pressure and longer duration of disease than
diabetics without SAF, and their risk of stroke during 3 years of
follow-up was increased by factor of 4.6.53 Detection of SAF on 72-h
Holter monitoring showed an association with the presence of ische-
mic lesions on magnetic resonance imaging in patients with transient
ischemic attack, and also with the severity of neurological deficit in
patients with stroke.56
Longer duration of Holter monitoring (7-day monitoring) in-
creases detection of SAF. The CRYSTAL-AF (CRYptogenic STroke
and underlying AtriaL fibrillation) trial demonstrated that longer term
monitoring had higher sensitivity in AF detection compared to 24-h
Holter monitoring.57 A recent meta-analysis showed that >_7-day
monitoring increase the detection of SAF in patients with cryptogenic
stroke or TIA by factor of 7.6 as compared to <72-h Holter monitor-
ing.58 In a study of 7-day Holter monitoring in patients after catheter
ablation for AF, authors analysed detection rates of AF recurrence
according to the (7-day monitoring—100% of AF recurrence epi-
sodes), duration of monitoring and demonstrated stepwise increase
in detection of AF recurrence with the extension of monitoring from
59%—24-h, 67%—48-h, 80%—72-h to 91% on days 4 and 5, and
95% on day 6.59
Comparison of AF screening strategies in patients with stroke re-
vealed that stopping screening after ECG in emergency room (phase
1) and any in-hospital monitoring method (phase 2) would have re-
sulted in detection of 50.2% and after out-of-hospital ambulatory
Holter monitoring (1- to 7-day monitoring, phase)—81.9% of post-
stroke AF diagnosed after phase 4 (mobile outpatients telemetry,
implantable loop recorders [ILR] and external loop recorders [ELR]).
There are several on-going trials testing AF screening strategies in
high-risk populations60–62 but more studies are needed to clarify the
role of Holter monitoring alone or in combination with other tools in
screening of subclinical tachyarrhythmias in high-risk populations.
Event recorders to detect sub-clinical
and silent atrial fibrillation
The 24-h Holter monitor represents the most established, but, as
outlined earlier, least sensitive device for continuous ECG monitoring
.................................................................................................
Table 12 Recommendations and fact box on use of
Holter monitoring to detect atrial tachyarrhythmias
Recommendations Class Supporting
references
Holter monitoring may be considered
for detection of SAF in high-risk pa-
tients who has no CIEDs and has no
indication for long-term event
monitoring
51, 53, 56, 58, 59
Holter monitoring may be used as a
step in screening strategy or in com-
bination with other screening tools to
improve detection of subclinical ar-
rhythmia and to select candidates for
long-term monitoring
51, 57, 60
Serial Holter monitoring may be con-
sidered if longer duration monitoring
tools are not available
51, 53, 56, 57, 59
Fact
ESVEA documented by Holter moni-
toring can be considered be a surro-
gate marker for paroxysmal AF
43, 48–51
AF, atrial fibrillation; ESVEA, excessive supraventricular ectopic activity; CIED,
cardiac implantable electronic device; SAF, silent atrial fibrillation.
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to detect silent AF, while implanted atrial-based PPMs and ICDs are
the most sensitive methods in detection of SCAF.7 Between these
two extremes, there are a variety of technologies which either con-
tinuously record the heart rhythm, or make intermittent record-
ings.44 The latter are either patient-activated, or have automatic AF
detection algorithms which use the ventricular rate and/or regularity
to define when AF is occurring. As SCAF is typically asymptomatic7
devices with automatic AF-detection algorithms have an advantage;
however, patient-activated devices may still be used by asking pa-
tients to make multiple random recordings while asymptomatic.
Devices may use dry or adhesive electrodes; may come in the form
of an adhesive patch,64 or resemble a typical Holter monitor.
....................................................................................................................................................................................................................
Table 13 Summary of key studies examining the utility of monitoring for the detection of previously undetected atrial
fibrillationa
Study (Year) Design (number) Monitoring device Population Definition of AF Prevalence of AF
EMBRACE68 (2014) RCT (286 with
monitor vs. 285
with Holter)
Braemar ER910AF event
monitor with dry elec-
trode belt; automatic
AF detection vs. 24-hr
Holter
Cryptogenic Stroke >_30 s Monitor: 16.1%
Detected within 90 days Holter 3.2
Grond et al.56 (2013) Cohort (1172) 72-hr Holter; Lifecard CF
(Spacelabs)
Ischemic stroke or TIA >30 s 4.3% after 72 hr
2.6% after 24 hr
Jabaudon et al.69 (2004) Cohort (149) 7-day; R-test Evolution II,
(Novacor)
Stroke or TIA Not stated ECG: 2.7%
24-hr Holter: 5%
ELR: 5.7%b
Tung et al.64 (2014) Cohort (1171) 14-day continuous ECG
monitor (Ziopatch;
iRhythm)
Stroke or TIA >30 s 5%
ASSERT-III67 (2015) Cohort (100) 30-day event monitor;
automatic AF detection
(Vitaphone 3100),
wireless central moni-
toring (m-Health
Solutions)
Age>_80 years with hyper-
tension and at least one
additional AF risk
factor)
>_6 min 15%
SCREEN-AF
(NCT02392754)70
Ongoing Cohort
(1800)
Two 14-day continuous
ECG monitors
(Ziopatch; iRhythm)
Age>_75 years without
prior AF
>_5 min Ongoing study
aAll exclude patients with a prior diagnosis of AF.
bTests done sequentially. ELR detected AF in 5.7% of patients with no AF on ECG or 24-hr Holter.
AF, atrial fibrillation; ECG, electrocardiogram; ELR, event loop recorder; hr, hour; RCT, randomized controlled trial;TIA, transient ischemic attack; ASSERT, ASymptomatic atrial
fibrillation and Stroke Evaluation in pacemaker patients and atrial fibrillation Reduction atrial pacing Trial; EMBRACE, 30-day Cardiac Event Monitor Belt for Recording Atrial
Fibrillation after a Cerebral Ischemic Event.
.................................................................................................
Table 15 Atrial fibrillation detection percentage in
embolic stroke of uncertain source (ESUS)
Study Year Study Design AF detection AF (%)
Dahal
et al.72
2015 Meta-analysis of
RCT
Cardiac moni-
toring
>_7 days vs.
<_2 days
13.8% vs. 2.5%
(P<0.001,
total 1149
patients)
Li et al.74 2015 Population-
based analysis
Paroxysmal AF
% in crypto-
genic stroke
vs. large/small
vessel disease
6% vs. 10%
(P=0.17, total
2555
patients)
AF, atrial fibrillation; RCT, randomized controlled trial.
.................................................................................................
Table 14 Fact box on use of event recorders to detect
subclinical and silent atrial fibrillation
Facts Supporting
references
A variety of technologies (continuous or inter-
mittent ECG recording) now exist for pro-
longed ambulatory cardiac monitoring to
detect SCAF and SAF
7, 56, 65, 68, 69, 70
Longer monitoring periods are associated with
a greater rate of SCAF and SAF detection
7, 31, 66
SAF, silent atrial fibrillation; SCAF, sub-clinical atrial fibrillation; ECG,
electrocardiography.
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A systematic review of monitoring studies, mostly done in post-
stroke populations, suggests that longer periods of monitoring are
associated with a higher rates of SAF detection.65 Technologies
which continuously record the ECG (e.g. Holter, 14-day or longer
term monitoring) have the advantage that they can calculate the fre-
quency of premature atrial contractions and short runs of atrial
tachycardia, which studies suggest are associated with an increased
risk of AF and stroke.48 Given the potentially prolonged periods of
monitoring, wireless devices with central monitoring facilitate earlier
physician recognition of SCAF.
Population screening studies have been done using single-point or
intermittent ECG monitoring.66 As monitoring technology has
evolved, various continuous monitoring technologies have been used
to study prevalence of undetected AF in patients without prior
stroke (Table 13). In the ASSERT III study, for example, which moni-
tored patients continuously for 30–60 days, 15% of patients 80 years
or older had at least one episode of SCAF >_ 6 min (Table 13).67
Although continuous monitoring provides a higher rate of SCAF de-
tection than that in studies using single-point and intermittent meth-
ods, it is more expensive. Ongoing research will define which
technologies are the most cost-effective for SCAF/SAF detection and
in which specific patient populations they should be applied.
....................................................................................................................................................................................................................
Table 16 Implantable loop recorders in detection of atrial fibrillation in cryptogenic stroke patients
Study (year) Number of
patients
AF detection
criteria
AF yield Mean/median
time to detect
(days)
Notes
Dion et al.80 (2010) 24 N/A 4.2% 435 All patients were <75 years of age;
EP testing of no value
Etgen et al.81 (2013) 22 6 min 27.3% 365
Rojo-Martinez et al.82 (2013) 101 2 min 33.7% 102
Cotter et al.83 (2013) 51 2 min 25.5%
SURPRISE84 (2014) 85 2 min 16.1%
CRYSTAL AF41 (2014) 221 >30 s 12.4% (1 year) 41 Small number of patients followed for 3 years
30% (3 years)
Ziegler et al.71 (2015) 1247 12.2% 182
Afzal et al.73 (2015) 1170 23.3% 365
Bernstein et al.75 Crystal AF Trial (2015) 212 20.9% 365 AF % in cryptogenic stroke with or
without brain infarction, topography
verification
AF, atrial fibrillation; CRYSTAL AF, CRYptogenic STroke and underlying AtriaL fibrillation; EP, electrohysiological; SURPRISE, Stroke Prior to Diagnosis of Atrial Fibrillation
Using Long-term Observation with Implantable Cardiac Monitoring Apparatus Reveal. Modified from reference.71
.................................................................................................
Table 17 Predictors of atrial fibrillation in cryptogenic
stroke population
Study Predictors of atrial fibrillation
Cotter et al.83 (2013) Age
Frequent atrial premature beats
Inter-atrial conduction block
Increased left atrial volume
CRYSTAL AF41 (2014) Age (U and M)
CHADS2 score (U)
PR interval (U and M)
Frequent atrial premature beats (U)
Diabetes (U)
M, multivariate; U, univariate; CRYSTAL AF, CRYptogenic STroke and underlying
AtriaL fibrillation.
.................................................................................................
Table 18 Recommendations on use of implantable
loop recorders and anticoagulation in cryptogenic
stroke
Recommendations Class Supporting
references
Outside of the research con-
text patients with crypto-
genic stroke may not
receive an ILR
26, 84, 85, 87
Patients with cryptogenic
stroke may receive antico-
agulation (based upon
brain imaging) after a
negative comprehensive
cardiac and vascular
investigation
26, 84, 85, 87
*The recommendations are based on the IMPACT trial data.26
See grading EHRA evidence grading for yellow heart—Table 1.
ILR, implantable loop recorder.
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Cryptogenic stroke and subclinical
atrial tachyarrhythmias
Cryptogenic stroke is defined as an embolic (defined by brain imaging
characteristics) cerebrovascular infarct for which no underlying cause
can be identified after full cardiovascular evaluation including exclu-
sion of intracranial shunts and carotid/vertebral arterial disease by ap-
propriate imaging studies, and ‘thrombogenic’ arrhythmias such as
AF, atrial flutter and, more recently, high frequency atrial premature
beats by continuous electrocardiographic monitoring.
Large scale randomized trials and meta-analyses have shown that
the prevalence of AF becomes higher as the monitoring periods are
longer (Tables 15 and 16).71–73 For example, continuous arrhythmia
monitoring for periods up to 1 year in patients with cryptogenic
stroke show an AF prevalence to be 20%.73 However, the topog-
raphy (shape, size and location) of the cerebral ischemic infarction
area is not related to AF prevalence.74,75
There is much similarity between the phenotype of cryptogenic
stroke (embolic stroke of uncertain source [ESUS]) and AF-related
stroke. Risk stratification of reccurent stroke can be performed in
ESUS using the CHA2DS2-VASc score, as with AF-related stroke.
76
Also, stroke severity in ESUS was shown to be similar to AF-related
strokes,77 though in women AF–related stroke was accompanied by
more disabling symptoms.78
Implantable loop recorders in patients
with cryptogenic stroke
Several randomized studies have compared standard follow-up
after cryptogenic stroke with implanted monitoring using remote
data acquisition, while most studies were observational reporting
findings in patients with stroke, who received monitor after full
clinical evaluation.79 Although in some cases the implanted device
was not fully capable of automated detection of AF,80 such devices
are generally associated with more rapid identification of AF than
less intensive routine follow-up. Recent meta-analysis of detection
rates of new-onset AF after stroke or transient ischemic attack has
demonstrated that the increase in monitoring time increases detec-
tion rates of the arrhythmia up to 16.9% with ILR, resulting in a cu-
mulative detection rate of every 4th case of AF compared with
ambulatory Holter monitoring (10.7%) and in-hospital monitoring
(5.2%) (Table 11).60
Despite apparent discrepancies in detection rates which are likely
related to patient selection factors and varying device characteristics/
settings (Table 16), there are common findings with regard to pre-
dictors of AF (Table 17).41,80–84
With regard to trends over time, most studies have observed that
detection rates of AF increase over time.41 Although implantable
monitors could be utilized for AF detection after cryptogenic stroke,
this strategy has not been shown to have clinical utility in regard to fu-
ture stroke prevention and its cost-effectiveness compared with an
empiric anticoagulation strategy remains speculative given the sub-
stantial expense of the devices. In light of the IMPACT (Randomized
trial to IMProve treatment with AntiCoagulanTs in patients with
Atrial Fibrillation) primary prevention data26 in which temporal dis-
sociation of arrhythmia and embolic events was definitively demon-
strated in a randomized trial where rapid anticoagulation after
identification of AF had no effect upon stroke outcomes, we cannot
justify an expensive monitoring strategy using implantable devices after
embolic stroke unless this is part of an investigation in which empiric
anticoagulation after cryptogenic stroke is the comparison group.
A rapidly evolving recent understanding of fibrotic pathology and
the pro-thrombotic characteristics of blood sampled from the left
atrium in patients with AF have led to a new paradigm of understand-
ing the mechanism of stroke; AF in this framework is not directly
causal, but is a marker and an amplifier of underlying atrial pathology
in which the arrhythmia itself is not a necessary condition for throm-
bus formation.85,86
Hand-held ECG detection of silent atrial
fibrillation in stroke patients
It has been shown that prolonged continuous monitoring detects
increased number of undiagnosed episodes of AF in patients after is-
chaemic stroke.87 However, prolonged continuous ECG monitoring
can also be associated with poorer compliance and high costs.
Brief intermittent ECG monitoring over a long time period
(30 days) is a low-cost non-invasive alternative method. Intermittent
arrhythmia screening with handheld electrocardiogram (ECG) has
shown to be significantly more sensitive in the detection of silent AF
compared to conventional 24-h Holter-ECG88,89 as well as in one
study of patients who had suffered an ischaemic stroke/TIA. In that
observational prospective controlled study, 249 consecutive patients
with a recent stroke/TIA without a history of AF were recruited,
within 14 days from the index event.90 Those investigators per-
formed an ambulatory continuous 24-h Holter-ECG recording be-
fore or within the first few days after hospital discharge.
Simultaneously, patients were equipped with a handheld ECG re-
corder and instructed to perform 10 s rhythm recordings once in the
morning and once in the evening for 30 days and in case of any ar-
rhythmia symptoms. A total of 17 patients were diagnosed with AF.
Intermittent handheld ECG recordings detected AF in 15 patients
and 2 exclusively by 24 h continuous ECG. In three patients, AF was
diagnosed by both methods. The ability to detect AF was significantly
better for the handheld ECG compared with the Holter-ECG
(P = 0.013). The total prevalence of AF was 6.8% and increased to
11.8% in patients >_75 years. An economic evaluation estimated that
.................................................................................................
Table 19 Fact box on use of hand-held ECG devices to
detect silent atrial fibrillation in stroke patients
Facts Supporting
references
Hand-held electrocardiogram devices can
be inexpensive, cost-effective, and non-
invasive tools for screening of silent inter-
mittent AF episodes, for example, in pa-
tients with ischemic stroke or TIA
without a history of AF
90–93
AF, atrial fibrillation; ECG, electrocardiogram; TIA, transient ischamic attack.
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silent AF screening by intermittent ECG recordings in 75-year-old
patients with a recent ischaemic stroke is a cost-effective use of
health care resources saving both costs and lives and improving the
quality of life.91
Smartphone ECG application to
detect silent atrial fibrillation
Recent studies indicate that it is technically feasible to identify AF
automatically using a simple electrode attachment for a smart-
phone92,93; in addition, community based screening using such
consumer technology has been shown to identify AF in 1.5% of a
high-risk population attending retail pharmacies.89 However,
whether detection of truly silent AF is valuable at all is a question that
remains unresolved: either there is a clinical concern regarding the
relationship between non-specific symptoms and arrhythmia (in
which case the AF is technically not silent), or the identification of
truly silent AF raises complex questions for which no clear answers
in relation to management are currently apparent.94 While there is
an established relationship in the pacemaker population between
overall burden of AF and stroke, the similarly well-established tem-
poral dissociation of arrhythmia episodes and stroke presents a para-
dox that will likely be clarified by ongoing prospective studies such as
Tactic AF and REACT.COM study which use continuous monitoring
to drive intermittent novel anticoagulant therapy.95,96
Role and limitations of imaging
techniques in stroke prediction in
silent atrial fibrillation
Although the CHA2DS2-VASc score is important in prediction of
stroke risk in patients with AF, many patients with score 0–1 may still
present with a stroke. Imaging techniques have focused on anatom-
ical and functional properties of the left atrium (LA) as well as the left
atrial appendage (LAA). Both LA/LAA enlargement and reduced
function have been associated with AF and stroke.85,97–99
Various LAA variables have been independently associated with an
increased risk of thromboembolic events. The LAA shape (an ana-
tomical parameter), but also markers of reduced LAA function such
as dense spontaneous echo contrast or thrombi, but also reduced
flow have been independently associated with an increased risk of
thromboembolic events.85,97,98 Optimal assessment of LAA size and
anatomy is obtained with 3-dimensional imaging techniques such as
multi-detector row computed tomography (MDCT) or magnetic
resonance imaging (MRI), whereas the different functional param-
eters are derived from transthoracic or transesophageal
echocardiography.100
The LA variables that may be relevant for development of stroke,
can also be divided into anatomical and functional parameters. LA
size can be measured with echocardiography; historically, diameters
have been used, but volumetric measures may be preferred. These
can be obtained with 3-dimensional echocardiography, but also with
MDCT or magnetic resonance imaging (MRI).85,97,98 Another marker
that appears relevant for the development of AF and has also been
related to stroke, is the presence and extent of LA fibrosis.85,97,98
This can roughly be estimated with transthoracic echocardiography
using integrated back scatter, but is more precisely quantified with
contrast-enhanced MRI.101
Functional parameters are derived mostly from echocardiography.
For example, LA function consists of three parts, namely the reser-
voir function (filling of the LA during left ventricular systole), the con-
duit function (acting as a conduit between the pulmonary veins and
the left ventricle during early diastole, reflected by the E-wave on
Doppler echocardiography) and the active booster pump function
(LA contraction, reflected by the A-wave on Doppler echocardiog-
raphy).98 Advanced measurement of these variables can be per-
formed with 3-dimensional echocardiography. More recently,
quantification of the active deformation (strain) of the LA has been
demonstrated with echocardiography and MRI.85,97,98
Finally, there is a clear relation between the anatomical and
functional LA parameters. LA dilatation is often associated with
LA fibrosis, which in turn results in reduced LA function and
specifically LA strain. An indirect marker of LA fibrosis is the
assessment of the electro-mechanical delay or prolonged totala-
trial activation time; this can be expressed by the time delay be-
tween the P-wave (on the ECG) and the mechanical activation of
the LA (the so-called PA-TDI, as derived from echocardiographic
tissue Doppler imaging).98
All of the aforementioned parameters are related to development
of AF and subsequent stroke.
Stroke risk assessment and
prevention strategies in
subclinical atrial tachyarrhythmias
Arrhythmia burden whether assessed by all episodes, longest epi-
sodes or number of episodes all show a relationship to annual
stroke/TE rates.19 For example, the absolute rate of stroke in
ASSERT increased with increasing CHADS2 score, ranging from a
stroke/TE rate of 0.56%/year at CHADS2 score 1, to 1.29% at
CHADS2 score 2 and 3.78%/year with CHADS2 score >2. Of note,
.................................................................................................
Table 20 Recommendations on stroke prevention in
subclinical atrial tachyarrhythmias
Recommendations Class Supporting
references
The presence of AHRE >5 min is associated
with an increased risk of stroke/SE espe-
cially in the presence of >_ 2 stroke risk
factors using the CHA2DS2-VASc score.
Thus, OAC should be considered in such
patients, whether as a NOAC or well
controlled VKA with TTR>70%.
5, 38
AHRE, atrial high rate episode; NOAC, non-vitamin K antagonist oral anticoagu-
lant; OAC, oral anticoagulation; SE, systemic embolism; TTR, time in the thera-
peutic ranges; VKA, vitamin K antagonist.
Device-detected subclinical atrial tachyarrhythmias : EHRA consensus document 1571
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
the event rates at CHADS2 0 and 1 were lower than those seen for
corresponding CHADS2 score event rates seen in the general AF
population. Until more evidence is forthcoming, stroke(and bleeding
risk in such patients should be assessed according to established risk
assessment tools, such as the CHA2DS2-VASc (for stroke) and the
HAS-BLED (for bleeding) risk scores.102,103 A high HAS-BLED score
is not a reason to withhold OAC, but to indicate the patient poten-
tially at risk of bleeding for more regular review and follow-up, assess
changes in the score over time, and to address the potentially revers-
ible bleeding risk factors.104
Given that all clinical risk scores have only modest predictive value
for precise risk assessment, the initial step should be the identification of
‘low risk’ patients (CHA2DS2-VASc score 0 in males, 1 in females) who
do not need any antithrombotic therapy; the subsequent step is to con-
sider stroke prevention (which is OAC) in patients with >_1 stroke risk
factors, with a clear recommendation for OAC in those with
CHA2DS2-VASc score >_2. OAC refers to a NOAC or well controlled
VKA, with time in the therapeutic range (TTR) >70%, given that the net
clinical benefit for treatment is evident even with one stroke risk fac-
tor.105 Most guidelines give a preference for the NOACs over VKA,
given the efficacy, safety and convenience of the latter1,106 as evident
from randomized trials and increasing ‘real world’ evidence.107–109
A TTR of >70% is associated with the best efficacy and safety of the
VKAs, and a good TTR can be predicted by various clinical risk factors
encompassed within the SAMe-TT2R2 score.
110 The latter score is a
simple clinical score that includes the common factors associated with
....................................................................................................................................................................................................................
Table 21 Studies on cost-effectiveness of device-based screening for silent atrial fibrillation after ischemic stroke
Study (Year) Type of Evaluation and
Health Care System
Patients Population Study Design Main Study Findings
Kamel et al.116 (2010) A semi-Markov model to
compare the cost and util-
ity of warfarin vs. aspirin to
prevent stroke in patients
with AF under a US payer
perspective.
Hypothetical cohort of 70-
year-old AF patients with a
prior ischemic stroke and
no contraindication to
warfarin
Meta-analysis was used to deter-
mine the yield of 7-days outpa-
tient cardiac monitoring which
could detect AF (5.9% detect-
ing rate vs. 1.45% with stand-
ard care) and trigger the
prescription of warfarin vs.
standard care with aspirin and
no monitoring after ischemic
stroke.
Outpatient cardiac monitor-
ing is cost-effective over a
wide range of model in-
puts (cost-utility ratio of
outpatient monitoring
would be $13 000 per
QALY gained), but the op-
timal duration and method
of monitoring is unknown.
Levin et al.91 (2015) Markov model to estimate
the cost and QALY of oral
anticoagulants vs. no ther-
apy to prevent stroke in
patients with AF under a
Sweden healthcare system.
Hypothetical cohort of 75-
year-old AF patients with a
recent ischemic stroke and
followed for 20 years
A decision analytic model com-
bining the use of an observa-
tional prospective controlled
study and epidemiological data
to determine the yield of inter-
mittent ECG recording using a
handheld device (6% detection
of AF) and 24-h Holter moni-
toring (0.8% detection of AF)
vs. no monitoring, which could
detect AF and trigger the pre-
scription of OAC.
Intermittent handheld ECG
screening is cost-effective
use of health care re-
sources saving cost and
lives, and improving qual-
ity of life (gain of 29 life-
years or 23 QALYs, and
cost saving of e55400
after 7 years, assuming
that 85% of detected AF
patients received lifetime
OAC).
Diamantopoulos
et al.118 (2016)
Markov model to compare
the cost and lifetime
QALYs of NOAC vs. as-
pirin to prevent stroke in
patients with AF under UK
National Health Service
perspective.
Hypothetical cohort of pa-
tients (mean age 62-year
old) with a recent crypto-
genic stroke or transient is-
chemic attack, allocated to
receive either an ICM vs.
standard of care as
observed in the CRYSTAL-
AF trial.
A deterministic analytic model
combining the use of data from
the CRYSTAL-AF and with
models used in previous
National Institute for Health
and Care Excellence (NICE)
assessments of AF treatments
to determine the yield of ICM
(8.9%, 12.4% and 30% detect-
ing AF at 6, 12 and 36 months)
vs. no monitoring which could
detect AF and trigger the pre-
scription of NOAC.
Implantable cardiac monitors
are a cost-effective diag-
nostic tool for the preven-
tion of recurrent stroke in
cryptogenic stroke pa-
tients (cost per QALY
gain was estimated to be
£17 175 and £13 296 with
the use of NOAC, and
warfarin, respectively).
AF, atrial fibrillation; CUR, cost-utility ratio; ECG, electrocardiogram; ICM, implantable cardiac monitoring; NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulants;
QALY, quality adjusted life-year.
1572 B. Gorenek et al.
Downloaded from https://academic.oup.com/europace/article-abstract/19/9/1556/3952563
by guest
on 21 February 2018
good international normalized ratio (INR) control, such that a score of
0–2 is associated with a good TTR, while a patient with a score of >2 is
less likely to achieve a good TTR, such that more regular review and
INR checks, as well as education and counselling are needed if a VKA is
used—or to use a NOAC instead (rather than impose a ‘trial of VKA’
which can be associated with an excess of thromboembolism while the
INR control is suboptimal.111,112
Other uncertainties remain. Although AHRE was associated with
an increased risk of ischemic stroke and systemic embolism, there
was a lack of a distinct temporal association between AHRE and the
actual event.24–26 Thus, AHRE could simply be a risk marker for
stroke, or reflect an indirect mechanism related to multiple comor-
bidities associated with stroke. For example, in patients with a high
CHA2DS2-VASc score, ischaemic stroke, thromboembolism and
mortality rates with or without AF are broadly similar.113,114
One possible explanation may be that not all AHRE episodes are
definitely AF. In an ancillary analysis from the ASSERT study,38 for ex-
ample, when using a cutoff of >6 min and >190 beats/min, the rate of
false-positive AHREs was 17.3%, making a review of device electro-
grams necessary. However, for AHREs that are lasting >6 h, the rate
of false positives was much lower, at 3.3%. Hence, rather than refer-
ring to these as AHRE, there is a suggestion to (as described earlier)
use the term ‘subclinical atrial tachyarrhythmias’ given the lower
events rates seen compared to ‘conventional’ ECG-defined AF and
the false positive electrograms.
What is less clear is the required ‘burden’ of the arrhythmia (that
is, AF episodes and duration) necessary for precipitating stroke and
TE. Recent results of ASSERT trial, demonstrated that only episodes
longer than 24 h of duration were associated with three-fold increase
in stroke rate as compared to episodes of shorter duration.115 Also,
the number of AHRE episodes per day—as well as AF burden
(whether quantified by duration or number of AHRE)—can vary
greatly, and the paroxysms of AF are frequently asymptomatic.
Ongoing studies (see relevant section below) will address the im-
pact of OAC on reducing stroke/TE in patients with AHRE detected
on devices. As mentioned earlier, there is a positive net clinical bene-
fit for OAC in overt AF with the presence of >_1 stroke risk
factors;105 however, this benefit is less clear for AHRE, especially
where arrhythmia burden is low.
Cost-effectiveness of screening for
silent AF after ischemic stroke
The improvement of the sensitivity and specificity for AF detection
using different device-based methods, such as handheld ECG de-
vice,91 external68 or implantable cardiac recorders41 as compared to
surface ECG or 24-h Holter monitoring have the potential to in-
crease the yield to identify silent AF as aetiology for ischemic stroke.
The cost-effectiveness of different mobile devices for screening of AF
in the primary care setting have been evaluated by the National
Institute for Health and Care Excellence (NICE) of UK. Both the
WatchBP Home A (https://www.nice.org.uk/guidance/mtg13/chap
ter/5-Cost-considerations) and AliveCor Heart Monitor device
(https://www.nice.org.uk/advice/mib35/chapter/Evidence-review) are
more cost-effective than portable ECG device in detecting silent AF
and preventing stroke in primary care setting. Nevertheless, there
are only limited cost-effectiveness analyses to determine whether
these screening methods should be implemented for screening for si-
lent AF after ischemic stroke in whom no aetiology can be deter-
mined (i.e. cryptogenic stroke) (Table 21).
In a meta-analysis, Kamel et al.116 have demonstrated that 1 week
of outpatient cardiac monitoring for screening of silent AF after
cryptogenic stroke is cost-effective compared with no monitoring in
a US-based health care system. Based on a Swedish cohort, Levin
et al.91 have shown that brief, intermittent long-term ECG recording
with a handheld ECG device for screening of silent AF in cryptogenic
stroke is also more cost-effective compared to no screening or 24-h
Holter monitoring, and even cost-saving after 7 years of implementa-
tion. Recently, Diamantopoulos et al.117 performed a cost-
effectiveness analysis using data from the CRYSTAL-AF trial from a
UK-based health care system, and revealed that ILRs were a cost-
effective screening method for prevention of recurrent stroke in
cryptogenic stroke. While all these studies91,116,117 demonstrate that
device-based screening methods for silent AF after cryptogenic
stroke are cost-effective, several assumptions are included in these
models, including that the use of screening for AF in elderly high risk
populations (aged > 70 or 75 years old), and treatment with OAC
are highly effective for recurrent stroke prevention. Indeed, the effi-
cacy of OAC for prevention of recurrent stroke in cryptogenic
stroke will be addressed by two ongoing clinical trials.118,119
Moreover, direct comparisons between these different devices on
the cost-effectiveness of screening for silent AF in cryptogenic stroke
also require future investigation.
Current research gaps, ongoing
trials and future directions
There are convincing data that subclinical atrial tachyarrhythmias de-
tected by cardiovascular electronic devices in patients without clinic-
ally overt AF are associated with an increased risk of stroke.
However, several major aspects of this association remain unclear, as
summarized in Table 22.
Table 22 Major knowledge gaps regarding device-de-
tected atrial tachyarrhythmias
• Pathophysiologic link between device-detected atrial tachyarrhyth-
mias and stroke. Are subclinical tachyarrhythmias the cause or just a
marker of increased stroke risk? Type of strokes: embolic or
ischemic?
• Is there a threshold of tachyarrhythmia duration leading to an ele-
vated stroke risk?
• Can oral anticoagulation reduce stroke risk in patients with subclin-
ical device-detected atrial tachyarrhythmias? Is there a threshold of
tachyarrhythmia duration for a beneficial effect of oral anticoagula-
tion? Do usual schemes for stroke risk stratification (e.g. CHA2DS2-
VASc) apply in this setting equally well as in patient with overt atrial
fibrillation?
• Potential role of different remote monitoring modalities: can it be
help for management of these patients and how?
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In particular, the pathophysiologic link between subclinical AF and
stroke is still obscure.28 The simple explanation of thrombus forma-
tion during subclinical tachyarrhythmic episodes followed by embo-
lization is challenged by the lack of a temporal relation between the
tachyarrhythmic episodes and the strokes as suggested in the
ASSERT and TRENDS studies,24,26 and confirmed by the IMPACT tri-
al.26 Thus, subclinical AF may rather be a marker of increased stroke
risk rather than a direct cause of thromboembolism. We also do not
know whether a certain duration of such episodes needs to be ex-
ceeded before an elevation of stroke risk is apparent. Respective data
are contradictory. For example, in the TRENDS study, tachyarrhyth-
mic episodes <5.5 h were not associated with an increased thrombo-
embolic risk20 whereas in the ASSERT study, episodes >_6 min
already led to a higher embolic risk,7 and in the Copenhagen Holter
Study even ESVEA was associated with a higher risk of stroke.47 Most
importantly, the benefit of oral anticoagulation based solely on
device-detected subclinical atrial tachyarrhythmias for reducing the
stroke risk has not yet been examined. Prospective clinical trials are
ongoing,13,14 and results are expected in 2019 (Table 2).
Consensus statements
.................................................................................................
Consensus statements Class
1. Incidence of subclinical AT/AF
varies depending on the clinical
characteristics of the popula-
tion studied.
2. • The vast majority of AF epi-
sodes are asymptomatic.
• Symptoms do not affect long-
term prognosis, but they do
increase the probability of
making a correct diagnosis and
offering proper treatment.
3. • The likelihood of detecting
subclinical AT/AF increases as
the duration of monitoring
lengthens.
• A variety of technologies, both
non-invasive and invasive now
exist for prolonged cardiac
monitoring to detect subclin-
ical AT/AF.
4. • The appearance of subclinical
AT/AF predisposes to
thromboembolic events.
• The minimum duration of AT/
AF episode or AT/AF burden
which confers increased
thromboembolic risk is not
precisely defined, but may be
Continued
.................................................................................................
Continued
Consensus statements Class
as brief as several minutes to
several hours.
• There is no established cut-
point for increase in risk, and
NO minimum duration that is
without risk.
5. • There does not seem to be a
close temporal relationship of
device-detected atrial arrhyth-
mias to the occurrence of
strokes.
• This implies that, in the major-
ity of device patients with
AHREs and thromboembolic
events, the mechanism of
stroke may not be related to
the AF episodes.
6. If available, review of stored intra-
cardiac electrograms to con-
firm diagnosis and exclude
artifact or reduce the effect of
oversensing/undersensing by
automated algorithms is
recommended
7. The presence or absence of
symptoms has no bearing on
determining the need for
anticoagulation
8. Consider no antithrombotic ther-
apy for any patient with
CHA2DS2-VASc score of 0 in
males or 1 in females, irre-
spective of AHRE
9. Consider oral anticoagulation for
AF burden (longest total dur-
ation of AF on any given day)
of > 5.5 h in patients with one
additional CHA2DS2-VASc risk
factor (i.e. score=1 in males
or = 2 in females)
10. For patients with two additional
CHA2DS2-VASc risk factors
(ie. >_2 in males, >_3 in females)
oral anticoagulation is recom-
mended for AF burden >5.5 h/
day (if there are no contraindi-
cations). Lower duration may
merit OAC if multiple risk fac-
tors are present.
11. • Novel user-friendly external
devices for AF detection have
the potential to increase the
Continued
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